Melching L I, Fisher W D, Lee E R, Mort J S, Roughley P J
Shriners Hospital for Children, McGill University, Montreal, Quebec, Canada.
Osteoarthritis Cartilage. 2006 Nov;14(11):1147-54. doi: 10.1016/j.joca.2006.05.014. Epub 2006 Jun 30.
Aggrecanase-1 [a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)-4] and aggrecanase-2 (ADAMTS-5) have been named for their ability to degrade the proteoglycan aggrecan. While this may be the preferred substrate for these enzymes, they are also able to degrade other proteins. The aim of this work was to determine whether the aggrecanases could degrade biglycan and decorin.
Biglycan, decorin and aggrecan were purified from human and bovine cartilage and subjected to degradation by recombinant aggrecanase-1 or aggrecanase-2. In vitro degradation was assessed by sodium dodecyl sulfate/polyacrylamide gel electrophoresis (SDS/PAGE) and immunoblotting, and the cleavage site in biglycan was determined by N-terminal amino acid sequencing. SDS/PAGE and immunoblotting were also used to assess in situ degradation in both normal and arthritic human articular cartilage.
Both aggrecanase-1 and aggrecanase-2 are able to cleave bovine and human biglycan at a site within their central leucine-rich repeat regions. Cleavage occurs at an asparagine-cysteine bond within the fifth leucine-rich repeat. In contrast, the closely related proteoglycan decorin is not a substrate for the aggrecanases. Analysis of human articular cartilage from osteoarthritic (OA) and rheumatoid arthritic (RA) joints showed that a biglycan degradation product of equivalent size is present in the extracellular matrix. No equivalent degradation product was, however, detectable in normal adult human articular cartilage.
Biglycan, which is structurally unrelated to aggrecan, can act as a substrate for aggrecanase-1 and aggrecanase-2, and these proteinases may account for at least part of the biglycan degradation that is present in arthritic cartilage.
聚集蛋白聚糖酶-1[一种具有血小板反应蛋白基序的解整合素和金属蛋白酶(ADAMTS)-4]和聚集蛋白聚糖酶-2(ADAMTS-5)因其能够降解蛋白聚糖聚集蛋白聚糖而得名。虽然这可能是这些酶的首选底物,但它们也能够降解其他蛋白质。这项研究的目的是确定聚集蛋白聚糖酶是否能够降解双糖链蛋白聚糖和核心蛋白聚糖。
从人和牛软骨中纯化双糖链蛋白聚糖、核心蛋白聚糖和聚集蛋白聚糖,并用重组聚集蛋白聚糖酶-1或聚集蛋白聚糖酶-2进行降解。通过十二烷基硫酸钠/聚丙烯酰胺凝胶电泳(SDS/PAGE)和免疫印迹评估体外降解,并通过N端氨基酸测序确定双糖链蛋白聚糖中的切割位点。SDS/PAGE和免疫印迹也用于评估正常和关节炎患者关节软骨中的原位降解。
聚集蛋白聚糖酶-1和聚集蛋白聚糖酶-2都能够在牛和人双糖链蛋白聚糖富含亮氨酸的中央重复区域内的一个位点进行切割。切割发生在第五个富含亮氨酸的重复序列内的天冬酰胺-半胱氨酸键处。相比之下,密切相关的蛋白聚糖核心蛋白聚糖不是聚集蛋白聚糖酶的底物。对骨关节炎(OA)和类风湿性关节炎(RA)关节的人关节软骨分析表明,细胞外基质中存在大小相当的双糖链蛋白聚糖降解产物。然而,在正常成人关节软骨中未检测到等效的降解产物。
与聚集蛋白聚糖结构无关的双糖链蛋白聚糖可作为聚集蛋白聚糖酶-1和聚集蛋白聚糖酶-2的底物,这些蛋白酶可能至少部分解释了关节炎软骨中存在的双糖链蛋白聚糖降解。